Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Multifactorial approach to the primary and secondary prevention of atherosclerosis.

Literature DB >> 22470251

Multifactorial approach to the primary and secondary prevention of atherosclerosis.

Abstract

We review data regarding the importance of various conventional and evolving atherosclerosis risk factors. In addition, we discuss a multifactorial approach to the primary and secondary prevention of major vascular events, including stroke.

Entities: Disease

Year: 2003 PMID： 22470251 PMCID： PMC3314409

Source DB: PubMed Journal: Ochsner J ISSN： 1524-5012

46 in total

1. Obesity and the heart: an ever-growing problem.

Authors: Carl J Lavie; Richard V Milani; Franz H Messerli
Journal: South Med J Date: 2003-06 Impact factor: 0.954

2. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors: S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal: N Engl J Med Date: 2000-01-20 Impact factor: 91.245

3. Effects of nonpharmacologic therapy with cardiac rehabilitation and exercise training in patients with low levels of high-density lipoprotein cholesterol.

Authors: C J Lavie; R V Milani
Journal: Am J Cardiol Date: 1996-12-01 Impact factor: 2.778

4. Effects of cardiac rehabilitation, exercise training, and weight reduction on exercise capacity, coronary risk factors, behavioral characteristics, and quality of life in obese coronary patients.

Authors: C J Lavie; R V Milani
Journal: Am J Cardiol Date: 1997-02-15 Impact factor: 2.778

5. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors:
Journal: Lancet Date: 1996-11-16 Impact factor: 79.321

6. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors: Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal: Lancet Date: 2002-03-23 Impact factor: 79.321

7. Fish consumption and risk of stroke in men.

Authors: Ka He; Eric B Rimm; Anwar Merchant; Bernard A Rosner; Meir J Stampfer; Walter C Willett; Alberto Ascherio
Journal: JAMA Date: 2002-12-25 Impact factor: 56.272

8. Cardiac rehabilitation programs markedly improve high-risk profiles in coronary patients with high psychological distress.

Authors: Surya M Artham; Carl J Lavie; Richard V Milani
Journal: South Med J Date: 2008-03 Impact factor: 0.954

Multifactorial approach to the primary and secondary prevention of atherosclerosis.

1. Obesity and the heart: an ever-growing problem.

2. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

3. Effects of nonpharmacologic therapy with cardiac rehabilitation and exercise training in patients with low levels of high-density lipoprotein cholesterol.

4. Effects of cardiac rehabilitation, exercise training, and weight reduction on exercise capacity, coronary risk factors, behavioral characteristics, and quality of life in obese coronary patients.

5. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

6. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

7. Fish consumption and risk of stroke in men.

8. Cardiac rehabilitation programs markedly improve high-risk profiles in coronary patients with high psychological distress.

Review 9. Management of lipids in primary and secondary prevention of cardiovascular diseases.

10. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.

1. Recent publications by ochsner authors.

2. The russert impact: a golden opportunity to promote primary coronary prevention.